Health Care/Hospital
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb®...
2021-06-02 21:00
9861
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs
SUZHOU, China, June 2, 2021 /PRNewswire/ -- On May 31, 2021, Porton Biologics Ltd. (hereinafter referred to as Portonbio) announced a strategic cooperation with Nanjing KAEDI Biotech, Inc. (hereinafter referred to as KAEDI).Portonbio will offer CMC services for KAEDI's CAR-T cell therapies with i...
2021-06-02 20:10
2181
PharmAbcine to Present at the BIO Digital International Convention 2021
DAEJEON, South Korea, June 2, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will participate in BIO Digital International Convention. The company will participate in...
2021-06-02 20:00
2961
Shanghai Asclepius Meditec and International Department of Central Committee of CPC Collaborate to Provide Emergency Support to Fight COVID-19 in Nepal
SHANGHAI, June 2, 2021 /PRNewswire/ -- The President of Asclepius Meditec – the
company behind the innovativeHydrogen Oxygen Generator with Nebulizer
2021-06-02 20:00
2266
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment...
2021-06-02 19:00
2283
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from
its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at
the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-
8, 2021 for the first time.
2021-06-02 16:14
1783
Therabody™ Announces Partnership With World-Renowned Footballer Cristiano Ronaldo
The Company Releases its Largest Global Ad Campaign since its Founding to Amplify the Importance of Recovery LOS ANGELES, June 2, 2021 /PRNewswire/ -- Therabody, the global leader in tech wellness and the creators of theTheragun®, announced today professional footballerCristiano Ronaldo as the c...
2021-06-02 15:00
3007
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealand * In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via...
2021-06-02 06:00
2171
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting
BEIJING and BOSTON, June 1, 2021 /PRNewswire/ -- Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held fromJune 4th to 8th. The first trial (poster #2580; NCT04481009) is designed to assess the safety...
2021-06-02 01:28
1998
GenScript ProBio and Neoletix signed a letter of intent on clinical and commercial production of recombinant human coagulation factor VIII
NANJING, China, June 1, 2021 /PRNewswire/ -- On June 1st 2021, GenScript ProBio and Neoletix (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as Neoletix) signed a letter of intent on cooperation for clinical and commercial production of human coagulation factor VIII. GenScript ProBio s...
2021-06-01 21:00
1974
Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes
SEOUL, South Korea, June 1, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon) announced that the results of an investigator-initiated clinical study on the effect of Enavogliflozin, originally developed as Type II Diabetes Treatment forhumans, on treating canine diabetes were publish...
2021-06-01 21:00
2297
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases
HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC) and neural...
2021-06-01 19:50
1653
Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials
Highlights: * Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman andPitt Hopkins syndromes * Positive outcome is an important milestone that enables Neuren to proceed with IND...
2021-06-01 18:00
1736
Introduce the World's First Biomedical Application Mask that Revolutionizes Face Mask to Resist Aerosol Transmission
TAIPEI, May 31, 2021 /PRNewswire/ -- Taer Innovation has won design awards including Good Design award from 2012 to 2014 Golden Pin Design award, Taiwan Excellence award in 2014 and Computex d&I award in 2014 for their products.The companyfocuses on medical innovation and technology. The company'...
2021-05-31 23:00
2373
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
* Samsung Biologics, a global leading CDMO, will add mRNA vaccine DS production capability to its existing facility by the first half of 2022 * The addition will enable Samsung Biologics to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill/finish ...
2021-05-31 19:00
3151
Revolutionary X-ray Technology From Australia to Transform American Airport Security
SeaTac chosen for Micro-X Inc's USA headquarters Official Opening at 10 am PDT, Friday May 28 855 S 192nd Street, Suite B600, Seattle, WA 98148 With: * Congressman Adam Smith, chair of the House Armed Services Committee * Brigadier Hugh Meggitt representing Australian Defence Staff, Embassy o...
2021-05-28 21:00
3605
Dr. Seungpil Yu will hold a retirement ceremony and conclude his 46-year term as a pharmaceutical executive.
SEOUL, South Korea, May 28, 2021 /PRNewswire/ -- Dr. Seungpil Yu is a living witness to the long history of Yuyu Pharma, which celebrated its 80th anniversary this year, having laid the foundation for Yuyu Pharma to continue to thrive well into its 100th year. While in the United States, Dr. Yu r...
2021-05-28 21:00
3964
Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management
* Expanding upon its existing ISO22301 certification, Samsung Biologics is now fully certified with Business Continuity Management System for Security and Resilience across all business areas * Samsung Biologics adds ISO50001, ISO45001, ISO14001 for Energy Management, Occupational Health and ...
2021-05-28 20:00
3581
AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson's Disease
SHANGHAI, May 27, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced thatChina's National Medical Products Administrati...
2021-05-28 08:00
2640
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test
* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage * Confirming the potential as a treatment for IPF and planning to apply for Ph.2 within 2021 * 2nd ODD granted as treatment for systemic sclerosis from the US FDA SEOUL, South Korea, May 27, 2021...
2021-05-27 21:00
2140
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 287 media titles]
2026-05-26 10:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 279 media titles]
2026-05-21 16:31
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
8699
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8419
